Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.
Identifieur interne : 000A93 ( PubMed/Curation ); précédent : 000A92; suivant : 000A94Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.
Auteurs : Sayed Sartaj Sohrab [Arabie saoudite] ; Sherif Aly El-Kafrawy [Arabie saoudite] ; Zeenat Mirza [Arabie saoudite] ; Mohammad Amjad Kamal [Arabie saoudite] ; Esam Ibraheem Azhar [Arabie saoudite]Source :
- Current pharmaceutical design [ 1873-4286 ] ; 2018.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : RNA, Small Interfering.
- drug effects : Middle East Respiratory Syndrome Coronavirus.
- Drug Delivery Systems, Drug Design, Humans.
Abstract
The MERS-CoV is a novel human coronavirus causing respiratory syndrome since April 2012. The replication of MERS-CoV is mediated by ORF 1ab and viral gene activity can be modulated by RNAi approach. The inhibition of virus replication has been documented in cell culture against multiple viruses by RNAi approach. Currently, very few siRNA against MERS-CoV have been computationally designed and published.
DOI: 10.2174/1381612823666171109112307
PubMed: 29119921
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A93
Links to Exploration step
pubmed:29119921Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.</title><author><name sortKey="Sohrab, Sayed Sartaj" sort="Sohrab, Sayed Sartaj" uniqKey="Sohrab S" first="Sayed Sartaj" last="Sohrab">Sayed Sartaj Sohrab</name><affiliation wicri:level="1"><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah</wicri:regionArea></affiliation></author><author><name sortKey="El Kafrawy, Sherif Aly" sort="El Kafrawy, Sherif Aly" uniqKey="El Kafrawy S" first="Sherif Aly" last="El-Kafrawy">Sherif Aly El-Kafrawy</name><affiliation wicri:level="1"><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah</wicri:regionArea></affiliation></author><author><name sortKey="Mirza, Zeenat" sort="Mirza, Zeenat" uniqKey="Mirza Z" first="Zeenat" last="Mirza">Zeenat Mirza</name><affiliation wicri:level="1"><nlm:affiliation>King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Fahd Medical Research Center, King Abdulaziz University, Jeddah</wicri:regionArea></affiliation></author><author><name sortKey="Kamal, Mohammad Amjad" sort="Kamal, Mohammad Amjad" uniqKey="Kamal M" first="Mohammad Amjad" last="Kamal">Mohammad Amjad Kamal</name><affiliation wicri:level="1"><nlm:affiliation>King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Fahd Medical Research Center, King Abdulaziz University, Jeddah</wicri:regionArea></affiliation></author><author><name sortKey="Azhar, Esam Ibraheem" sort="Azhar, Esam Ibraheem" uniqKey="Azhar E" first="Esam Ibraheem" last="Azhar">Esam Ibraheem Azhar</name><affiliation wicri:level="1"><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29119921</idno><idno type="pmid">29119921</idno><idno type="doi">10.2174/1381612823666171109112307</idno><idno type="wicri:Area/PubMed/Corpus">000A93</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A93</idno><idno type="wicri:Area/PubMed/Curation">000A93</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.</title><author><name sortKey="Sohrab, Sayed Sartaj" sort="Sohrab, Sayed Sartaj" uniqKey="Sohrab S" first="Sayed Sartaj" last="Sohrab">Sayed Sartaj Sohrab</name><affiliation wicri:level="1"><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah</wicri:regionArea></affiliation></author><author><name sortKey="El Kafrawy, Sherif Aly" sort="El Kafrawy, Sherif Aly" uniqKey="El Kafrawy S" first="Sherif Aly" last="El-Kafrawy">Sherif Aly El-Kafrawy</name><affiliation wicri:level="1"><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah</wicri:regionArea></affiliation></author><author><name sortKey="Mirza, Zeenat" sort="Mirza, Zeenat" uniqKey="Mirza Z" first="Zeenat" last="Mirza">Zeenat Mirza</name><affiliation wicri:level="1"><nlm:affiliation>King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Fahd Medical Research Center, King Abdulaziz University, Jeddah</wicri:regionArea></affiliation></author><author><name sortKey="Kamal, Mohammad Amjad" sort="Kamal, Mohammad Amjad" uniqKey="Kamal M" first="Mohammad Amjad" last="Kamal">Mohammad Amjad Kamal</name><affiliation wicri:level="1"><nlm:affiliation>King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Fahd Medical Research Center, King Abdulaziz University, Jeddah</wicri:regionArea></affiliation></author><author><name sortKey="Azhar, Esam Ibraheem" sort="Azhar, Esam Ibraheem" uniqKey="Azhar E" first="Esam Ibraheem" last="Azhar">Esam Ibraheem Azhar</name><affiliation wicri:level="1"><nlm:affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah</wicri:regionArea></affiliation></author></analytic><series><title level="j">Current pharmaceutical design</title><idno type="eISSN">1873-4286</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Drug Delivery Systems</term><term>Drug Design</term><term>Humans</term><term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term><term>RNA, Small Interfering (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Conception de médicament</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term><term>Humains</term><term>Petit ARN interférent (pharmacologie)</term><term>Systèmes de délivrance de médicaments</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>RNA, Small Interfering</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Petit ARN interférent</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Delivery Systems</term><term>Drug Design</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Conception de médicament</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Humains</term><term>Systèmes de délivrance de médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The MERS-CoV is a novel human coronavirus causing respiratory syndrome since April 2012. The replication of MERS-CoV is mediated by ORF 1ab and viral gene activity can be modulated by RNAi approach. The inhibition of virus replication has been documented in cell culture against multiple viruses by RNAi approach. Currently, very few siRNA against MERS-CoV have been computationally designed and published.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29119921</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-4286</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Current pharmaceutical design</Title><ISOAbbreviation>Curr. Pharm. Des.</ISOAbbreviation></Journal><ArticleTitle>Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.</ArticleTitle><Pagination><MedlinePgn>62-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1381612823666171109112307</ELocationID><Abstract><AbstractText Label="BACKGROUND">The MERS-CoV is a novel human coronavirus causing respiratory syndrome since April 2012. The replication of MERS-CoV is mediated by ORF 1ab and viral gene activity can be modulated by RNAi approach. The inhibition of virus replication has been documented in cell culture against multiple viruses by RNAi approach. Currently, very few siRNA against MERS-CoV have been computationally designed and published.</AbstractText><AbstractText Label="METHODS">In this review, we have discussed the computational designing and delivery of potential siRNAs. Potential siRNA can be designed to silence a desired gene by considering many factors like target site, specificity, length and nucleotide content of siRNA, removal of potential off-target sites, toxicity and immunogenic responses. The efficient delivery of siRNAs into targeted cells faces many challenges like enzymatic degradation and quick clearance through renal system. The siRNA can be delivered using transfection, electroporation and viral gene transfer. Currently, siRNAs delivery has been improved by using advanced nanotechnology like lipid nanoparticles, inorganic nanoparticles and polymeric nanoparticles.</AbstractText><AbstractText Label="CONCLUSION">The efficacy of siRNA-based therapeutics has been used not only against many viral diseases but also against non-viral diseases, cancer, dominant genetic disorders, and autoimmune disease. This innovative technology has attracted researchers, academia and pharmaceuticals industries towards designing and development of highly effective and targeted disease therapy. By using this technology, effective and potential siRNAs can be designed, delivered and their efficacy with toxic effects and immunogenic responses can be tested against MERS-CoV.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sohrab</LastName><ForeName>Sayed Sartaj</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Kafrawy</LastName><ForeName>Sherif Aly</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirza</LastName><ForeName>Zeenat</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamal</LastName><ForeName>Mohammad Amjad</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Novel Global Community Educational Foundation, Hebersham, NSW 2770, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azhar</LastName><ForeName>Esam Ibraheem</ForeName><Initials>EI</Initials><AffiliationInfo><Affiliation>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Pharm Des</MedlineTA><NlmUniqueID>9602487</NlmUniqueID><ISSNLinking>1381-6128</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="Y">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">MERS-CoV</Keyword><Keyword MajorTopicYN="Y">RNA interference</Keyword><Keyword MajorTopicYN="Y">delivery</Keyword><Keyword MajorTopicYN="Y">designing</Keyword><Keyword MajorTopicYN="Y">nanoparticles.</Keyword><Keyword MajorTopicYN="Y">siRNA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29119921</ArticleId><ArticleId IdType="pii">CPD-EPUB-86780</ArticleId><ArticleId IdType="doi">10.2174/1381612823666171109112307</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000A93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:29119921
|texte= Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:29119921" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |